Get NeuroSense Therapeutics alerts:Read Our Latest Stock Report on NeuroSense TherapeuticsInsider Buying and Selling at NeuroSense TherapeuticsInstitutional Trading of NeuroSense TherapeuticsIn related news, CFO Or Eisenberg purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. Also, CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. NeuroSense Therapeutics Trading Down 7.2%NeuroSense Therapeutics stock opened at $0.50 on Friday. NeuroSense Therapeutics Company Profile(Get Free Report)NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. Featured StoriesReceive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.